Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines

Kitada, Noriaki; Takara, Kohji; Minegaki, Tetsuya; Itoh, Chihiro; Tsujimoto, Masayuki; Sakaeda, Toshiyuki; Yokoyama, Teruyoshi

doi:10.1007/s00280-007-0640-3

Cited by 58 publications

(37 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evaluating the relative cell uptake of liposomal-free platinum compounds in 8 cancer cell lines, several authors reported similar results than what was measured in our study with the F98 cells [22,23]. The lowest cell uptake was obtained after incubation with carboplatin, while an equivalent or slightly higher accumulation was reported with oxaliplatin compared to cisplatin.…”

Section: Discussionsupporting

confidence: 88%

“…The relative level of cancer cell toxicity induced by cisplatin, oxaliplatin and carboplatin measured on the F98 cells was similar to the results reported by other groups on human glioma cell lines and other cancer cell lines. The most efficient platinum compound, oxaliplatin, generally also reached the highest cell uptake [22,23,26]. Conversely, the liposomal formulations Lipoxal ™ and Lipoplatin ™ enhance the accumulation in the cancer cells but result in a lower cytotoxicity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation

et al. 2009

View full text Add to dashboard Cite

Despite significant advances, the radiotherapy and chemotherapy protocols marginally improve the overall survival of patients with glioblastoma. Lipoplatin ™ , and Lipoxal ™ , the liposomal formulations of cisplatin and oxaliplatin respectively, were tested on the F98 glioma cells for their ability to improve the cell uptake and increase the synergic effect when combined with ionizing radiation. The cytotoxicity and synergic effect of platinum compounds were assessed by colony formation assay, while the cellular uptake was measured by Inductively Coupled Plasma Mass Spectrometer (ICP-MS). After 4 h exposure with platinum compounds, cells were irradiated (1.5 to 6.6 Gy) with a 60 Co source. The liposomal formulations were compared to their liposome-free analogs and to carboplatin. The concomitant treatment of F98 cells with carboplatin and radiation produced the highest radiosensitizing effect (30-fold increase). Among the platinum compounds tested, Lipoplatin ™ produced the most promising results. This liposomal formulation of cisplatin improved the cell uptake by 3-fold, and its radiosensitizing potential was enhanced by 14-fold. Although Lipoxal ™ can potentially reduce the adverse effect of oxaliplatin, a synergic effect with radiation was measured only when incubated at a concentration higher than its IC50. Conversely, concomitant treatment with cisplatin did not result in a synergic effect, as in fact a radioprotective effect was measured on the F98 cells. In conclusion, among the five platinum compounds tested, carboplatin and Lipoplatin ™ showed the best radiosensitizing effect. Lipoplatin ™ seems the most promising since it led to the best cellular incorporation and has already been reported to be less neurotoxic than other platinum compounds.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The anticancer activity and resistance to platinum agents have been considered to be related to the DNA repair pathway, nucleotide excision repair, base excision repair, mismatch repair, and double-strand break repair, or the substrate specificity of copper transporters, CTR1, ATP7A, and ATP7B (Kelland, 2007). However, recently, we and others reported the contribution of organic cation transporters in the cellular transport of platinum agents (Ciarimboli et al, 2005;Yonezawa et al, 2005Yonezawa et al, , 2006Zhang et al, 2006;Yokoo et al, 2007;Kitada et al, 2008). Zhang et al (2006) reported that the effect of oxaliplatin against colon cancer was related to the expression of hOCT1 and hOCT2.…”

Section: Discussionmentioning

confidence: 99%

“…Zhang et al (2006) reported that the effect of oxaliplatin against colon cancer was related to the expression of hOCT1 and hOCT2. Kitada et al (2008) reported that the levels of ATP7A and hOCT1 mRNA affect the sensitivity to oxaliplatin. However, we reported that oxaliplatin was transported by both human and …”

Section: Discussionmentioning

confidence: 99%

Significance of Organic Cation Transporter 3 (SLC22A3) Expression for the Cytotoxic Effect of Oxaliplatin in Colorectal Cancer

Yokoo

Masuda²,

Yonezawa

et al. 2008

Drug Metab Dispos

View full text Add to dashboard Cite

ABSTRACT:The effect of oxaliplatin against colorectal cancer is superior to that of cisplatin, but the molecular mechanism(s) involved is not clear. We found previously that oxaliplatin, but not cisplatin, was transported by human (h) and rat organic cation transporter 3 (OCT3)/SLC22A3. In the present study, we examined whether hOCT3 was significantly involved in the oxaliplatin-induced cytotoxicity and accumulation of platinum in colorectal cancer. The level of hOCT3 mRNA in the colon was 9.7-fold higher in cancerous than in normal tissues in six Japanese patients (P ‫؍‬ 0.0247). In human colorectal cancer-derived cell lines, the mRNA of hOCT3 was highly expressed compared with that of other organic cation transporters. The release of lactate dehydrogenase (LDH) and accumulation of platinum with oxaliplatin treatment were increased in SW480 cells transfected with hOCT3 cDNA compared with empty vector-transfected cells. T84 and SW837 cells, with high levels of hOCT3, released more LDH and accumulated more platinum after oxaliplatin treatment than low hOCT3-expressing cells such as SW480, HCT116, HT29, and Lovo. However, the amount of platinum accumulated after cisplatin treatment did not differ among these six cell lines. The levels of hOCT3 expression in colon and rectum were also higher in cancerous than in normal tissues in Caucasian patients as determined by dot blotting. In conclusion, the hOCT3-mediated uptake of oxaliplatin into the cancers was suggested to be important for its cytotoxicity, and hOCT3 expression may be a marker for cancer chemotherapy including oxaliplatin.

show abstract

“…Downregulation in HCC could be responsible for a worse or lacking response towards platin treatment. In colorectal cancer OCTs are determinants of oxaliplatin cytotoxicity [11,[25][26][27]. Moreover, SLC22A3 expression in renal cell carcinoma cell lines enhances the sensitivity towards chemotherapeutics as melphalan, irinotecan and vincristin [28].…”

Section: Discussionmentioning

confidence: 99%

285 Downregulation of Organic Cation Transporters Oct1 (Slc22a1) and Oct3 (Slc22a3) in Human Hepatocellular Carcinoma and Their Prognostic Significance

Knapstein

Heise

Lautem

et al. 2012

Journal of Hepatology

View full text Add to dashboard Cite

Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines

Abstract: Some factors affecting the sensitivity of tumor cells to platinum derivatives were proposed, and will provide useful information for cancer chemotherapy with platinum derivatives.

Cited by 58 publications

References 17 publications

Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation

Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation

Significance of Organic Cation Transporter 3 (SLC22A3) Expression for the Cytotoxic Effect of Oxaliplatin in Colorectal Cancer

285 Downregulation of Organic Cation Transporters Oct1 (Slc22a1) and Oct3 (Slc22a3) in Human Hepatocellular Carcinoma and Their Prognostic Significance

Contact Info

Product

Resources

About